{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-016881","form_type":"8-K","ticker":"CLNN","cik":"0001822791","company_name":"Clene Inc.","filed_at":"2026-05-14T12:02:05+00:00","discovered_at":"2026-05-14T12:05:00.583021+00:00","generated_at":"2026-05-14T12:06:57.227436+00:00","sec_items":["1.01","2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Clene plans Q3 2026 NDA submission for CNM-Au8 ALS; Q1 net loss $8.1M, cash $5.9M","bullets":["FDA Type C meeting confirmed data may support NDA under accelerated approval for ALS; submission planned Q3 2026.","May 2026: Amended $10M convertible debt; maturity extended to Aug 2027, monthly payments cancelled.","Q1 2026 net loss $8.1M ($0.69/share) vs $0.8M loss in Q1 2025; R&D down, other expense up from financing.","Cash $5.9M at Mar 31; with $7M May offering and $7M warrant exercises, runway expected into 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-016881","json":"https://secwatch.observer/filing/0001437749-26-016881.json","markdown":"https://secwatch.observer/filing/0001437749-26-016881.md","text":"https://secwatch.observer/filing/0001437749-26-016881.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1822791/000143774926016881/0001437749-26-016881-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1822791/000143774926016881/clnn20260116_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T12:06:57.227436+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}